Spatial Genomic Heterogeneity in Multiple Myeloma Revealed by Multi-region Sequencing

Overview

Journal Nat Commun

Specialty Biology

Date 2017 Aug 18

PMID 28814763

Citations 196

Authors

L Rasche

S S Chavan

O W Stephens

P H Patel

R Tytarenko

C Ashby

M Bauer

C Stein

S Deshpande

C Wardell

T Buzder

G Molnar

M Zangari

F van Rhee

S Thanendrarajan

C Schinke

J Epstein

F E Davies

B A Walker

T Meissner

B Barlogie

G J Morgan

N Weinhold

Affiliations

Soon will be listed here.

Abstract

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site is well-perfused, a rapid dissemination of "fitter" clones may be anticipated. However, an imbalanced distribution of multiple myeloma is frequently observed in medical imaging. Here, we perform multi-region sequencing, including iliac crest and radiology-guided focal lesion specimens from 51 patients to gain insight into the spatial clonal architecture. We demonstrate spatial genomic heterogeneity in more than 75% of patients, including inactivation of CDKN2C and TP53, and mutations affecting mitogen-activated protein kinase genes. We show that the extent of spatial heterogeneity is positively associated with the size of biopsied focal lesions consistent with regional outgrowth of advanced clones. The results support a model for multiple myeloma progression with clonal sweeps in the early phase and regional evolution in advanced disease. We suggest that multi-region investigations are critical to understanding intra-patient heterogeneity and the evolutionary processes in multiple myeloma.In multiple myeloma, malignant cells expand within bone marrow. Here, the authors use multi-region sequencing in patient samples to analyse spatial clonal architecture and heterogeneity, providing novel insight into multiple myeloma progression and evolution.

Citing Articles

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications.

Li S, Liu J, Peyton M, Lazaro O, McCabe S, Huang X Cancers (Basel). 2025; 17(4).

PMID: 40002248 PMC: 11852428. DOI: 10.3390/cancers17040653.

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.

Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B Nat Commun. 2025; 16(1):1824.

PMID: 39979252 PMC: 11842827. DOI: 10.1038/s41467-025-56486-6.

Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.

Oelschlager L, Kunstner A, Frey F, Leitner T, Leypoldt L, Reimer N Int J Mol Sci. 2025; 25(24.

PMID: 39769182 PMC: 11680055. DOI: 10.3390/ijms252413418.

Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy.

McAuley N, Cymer I, McAvera R, Hopkins A, Glavey S Eur J Haematol. 2024; 114(3):400-410.

PMID: 39632279 PMC: 11798765. DOI: 10.1111/ejh.14352.

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.

Martello M, Solli V, Mazzocchetti G, Solimando A, Bezzi D, Taurisano B Blood Cancer J. 2024; 14(1):208.

PMID: 39609411 PMC: 11605000. DOI: 10.1038/s41408-024-01185-6.

References

Bartel T, Haessler J, Brown T, Shaughnessy Jr J, van Rhee F, Anaissie E . F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114(10):2068-76. PMC: 2744568. DOI: 10.1182/blood-2009-03-213280. View

Zhang J, Fujimoto J, Zhang J, Wedge D, Song X, Zhang J . Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256-9. PMC: 4354858. DOI: 10.1126/science.1256930. View

Morgan G, Walker B, Davies F . The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12(5):335-48. DOI: 10.1038/nrc3257. View

Lopez-Anglada L, Gutierrez N, Garcia J, Mateos M, Flores T, San Miguel J . P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2009; 84(4):359-61. DOI: 10.1111/j.1600-0609.2009.01399.x. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Keats J, Chesi M, Egan J, Garbitt V, Palmer S, Braggio E . Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5):1067-76. PMC: 3412330. DOI: 10.1182/blood-2012-01-405985. View

Favero F, Joshi T, Marquard A, Birkbak N, Krzystanek M, Li Q . Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2014; 26(1):64-70. PMC: 4269342. DOI: 10.1093/annonc/mdu479. View

Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P . Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A. 2015; 112(47):E6496-505. PMC: 4664355. DOI: 10.1073/pnas.1519556112. View

Lonial S, Boise L, Kaufman J . How I treat high-risk myeloma. Blood. 2015; 126(13):1536-43. DOI: 10.1182/blood-2015-06-653261. View

10.

Walker B, Wardell C, Melchor L, Brioli A, Johnson D, Kaiser M . Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2013; 28(2):384-390. PMC: 3916874. DOI: 10.1038/leu.2013.199. View

11.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S . Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016; 6(7):e453. PMC: 5030385. DOI: 10.1038/bcj.2016.64. View

12.

Raab M, Lehners N, Xu J, Ho A, Schirmacher P, Goldschmidt H . Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 2016; 127(17):2155-7. DOI: 10.1182/blood-2015-12-686782. View

13.

Radbruch A, Muehlinghaus G, Luger E, Inamine A, Smith K, Dorner T . Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006; 6(10):741-50. DOI: 10.1038/nri1886. View

14.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan G, Crowley J . Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014; 124(20):3043-51. PMC: 4231416. DOI: 10.1182/blood-2014-07-552059. View

15.

Sottoriva A, Kang H, Ma Z, Graham T, Salomon M, Zhao J . A Big Bang model of human colorectal tumor growth. Nat Genet. 2015; 47(3):209-16. PMC: 4575589. DOI: 10.1038/ng.3214. View

16.

Greaves M, Maley C . Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. PMC: 3367003. DOI: 10.1038/nature10762. View

17.

Hao J, Lin D, Dinh H, Mayakonda A, Jiang Y, Chang C . Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat Genet. 2016; 48(12):1500-1507. PMC: 5127772. DOI: 10.1038/ng.3683. View

18.

Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A . Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013; 31(34):4325-32. DOI: 10.1200/JCO.2012.48.4923. View

19.

Weinhold N, Ashby C, Rasche L, Chavan S, Stein C, Stephens O . Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128(13):1735-44. PMC: 5043128. DOI: 10.1182/blood-2016-06-723007. View

20.

Nowakowski G, Witzig T, Dingli D, Tracz M, Gertz M, Lacy M . Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005; 106(7):2276-9. PMC: 1895270. DOI: 10.1182/blood-2005-05-1858. View